Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade B 22.49 -6.25% -1.50
ARRY closed down 6.25 percent on Friday, March 22, 2019, on 82 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ARRY trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 21 Slingshot Bullish Bullish Swing Setup -6.25%
Mar 21 Bollinger Band Squeeze Range Contraction -6.25%
Mar 21 Overbought Stochastic Strength -6.25%
Mar 20 New 52 Week Closing High Bullish -8.02%
Mar 20 Bollinger Band Squeeze Range Contraction -8.02%
Mar 20 New 52 Week High Strength -8.02%
Mar 20 Stochastic Reached Overbought Strength -8.02%
Mar 20 Upper Bollinger Band Walk Strength -8.02%

Older signals for ARRY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Chemistry Biopharmaceutical Cancer Pain Nasdaq Chemical Compounds Organic Compounds Treatment Of Cancer Breast Cancer Asthma Multiple Myeloma Inflammatory Diseases Chloroarenes Hepatitis C Phosphoinositide 3 Kinase Inhibitor Gastric Cancer Metastatic Solid Tumors Myelodysplastic Syndromes Array Biopharma Binimetinib Her2 Mek Inhibitor
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.76
52 Week Low 12.56
Average Volume 3,681,671
200-Day Moving Average 17.0047
50-Day Moving Average 21.1
20-Day Moving Average 23.3055
10-Day Moving Average 23.675
Average True Range 0.8581
ADX 38.28
+DI 28.4133
-DI 24.1184
Chandelier Exit (Long, 3 ATRs ) 22.1857
Chandelier Exit (Short, 3 ATRs ) 23.9443
Upper Bollinger Band 24.7307
Lower Bollinger Band 21.8803
Percent B (%b) 0.21
BandWidth 12.230589
MACD Line 0.6853
MACD Signal Line 0.8489
MACD Histogram -0.1636
Fundamentals Value
Market Cap 3.85 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -31.24
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.71
Resistance 3 (R3) 24.95 24.45 24.34
Resistance 2 (R2) 24.45 23.88 24.33 24.22
Resistance 1 (R1) 23.47 23.54 23.22 23.23 24.09
Pivot Point 22.97 22.97 22.85 22.85 22.97
Support 1 (S1) 21.99 22.40 21.74 21.75 20.89
Support 2 (S2) 21.49 22.06 21.37 20.76
Support 3 (S3) 20.51 21.49 20.64
Support 4 (S4) 20.27